Bladder Cancer – Epidemiology Insights and Disease Burden Report – 2020 To 2040

Bladder Cancer Epidemiology Insights and Disease Burden

Thelansis’s “Bladder Cancer Epidemiology Insights and Disease Burden Report – 2020 To 2040″ provides an analysis of disease burden, characterized by disease definition, prevalence, incidence, diagnosed cases, severity, comorbidities, and clinical manifestations. Potential patient flow dynamics in disease burden are driven by shifts in demographic indicators and their correlation with age and gender distribution over time. Changes in the reported cases and long-term survival of patients may depend on diet, lifestyle, comorbid conditions, and the availability of interventions or therapies.

Bladder Cancer Overview

Bladder cancer is a common urothelial tract malignancy driven by risk factors like smoking and somatic mutations (FGFR3, TP53). Painless hematuria is the cardinal symptom, with diagnosis confirmed via cystoscopy and CT urography. The therapeutic landscape across all stages has been entirely transformed by immunotherapy and antibody-drug conjugates (ADCs). In high-risk, BCG-naive non-muscle-invasive disease (NMIBC), management endoscopically via transurethral resection is optimized by the approved addition of durvalumab to intravesical BCG. For BCG-unresponsive variants, the paradigm utilizes the IL-15 superagonist Anktiva plus BCG or systemic pembrolizumab. For muscle-invasive disease (MIBC), standard care has shifted from simple neoadjuvant cisplatin to advanced perioperative regimens, incorporating either durvalumab plus gemcitabine/cisplatin or the blockbuster combination of enfortumab vedotin (EV) plus pembrolizumab. In the metastatic setting, the combination of EV and pembrolizumab stands as the undisputed first-line standard of care, relegating traditional platinum chemotherapy with maintenance avelumab to a fallback strategy, while erdafitinib targets FGFR3-altered tumors. Long-term surveillance remains vital.

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Deliverables format and updates*:

• Access to an interactive epidemiology platform with downloadable Excel and PPT files.
  • Global findings
  • G8 findings
  • Regional findings
  • Country-specific findings
• Others*: regular updates, customizations, epidemiologist support

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the content. Countries, subpopulations, and years of forecast can be customized as per client requirements.

Key business questions answered:

• 20-year historical and forecast data (2020–2040)
• Disease definition based on globally accepted and latest criteria (e.g., ICD-10 codes)
• Granular patient population coverage by year and geography
• Detailed segmentation by age, gender, subpopulations, comorbidities, line of therapies, etc.
• Patient funnels
• Country comparisons
• Relevant clinical variables (e.g., staging/classification/severity)

Insights driven by robust research and estimates:

• Published literature (e.g., peer-reviewed journal articles, registries, national surveys)
• Primary market research with KOLs
• RWD analysis using claims and EHR datasets
• Proprietary mathematical models (e.g., incidence-survival model; incidence- recurrence/progression-survival model)

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risk,etc.

2. Disease Context

• Disease definition, classification, etiology and pathophysiology, drug targets,etc.

3. Epidemiology

• Key takeaways
• Incidence / Prevalence
• Diagnosed and Drug-Treated populations
• Comorbidities
• Other relevant patient segments

4. Market Size and Forecast

• Key takeaways
• Market drivers and constraints
• Drug-class specific trends
• Country-specific trends

5. Competitive Landscape

• Current therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key current therapies – profiles and KOL insights
• Emerging therapies
  • Key takeaways
  • Notable late-phase emerging therapies – profiles, launch expectations, KOL insights
  • Notable early-phase pipeline

6. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)